MUC16 and pancreatic neoplasm: Of the antibody-drug conjugates tested in clinical trials in pancreatic cancer patients, none of them showed significant clinical activity, including the anti-SLC44A4 antibody-drug conjugate ASG-5ME [133], the anti-guanylyl cyclase C antibody-drug conjugate TAK-264 [132], the anti-MUC16 antibody-drug conjugate DMUC5754A [204], and the anti-mucin antibody-drug conjugate 90Y-clivatuzumab tetraxetan based on an interim analysis of a phase 3 trial (NCT01956812).